{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:34:04Z","timestamp":1751369644529,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03500-4","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T15:53:12Z","timestamp":1730821992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of risankizumab in Turkish adults with chronic plaque psoriasis: a one year single-center, retrospective, real-life study"],"prefix":"10.1007","volume":"316","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9483-6268","authenticated-orcid":false,"given":"Gulsen","family":"Akoglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyneb","family":"Tecik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"3500_CR1","doi-asserted-by":"publisher","unstructured":"Strober B, Menter A, Leonardi C et al (Epub 2020) Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol 34(12):2830\u20132838. https:\/\/doi.org\/10.1111\/jdv.16521","DOI":"10.1111\/jdv.16521"},{"key":"3500_CR2","doi-asserted-by":"publisher","unstructured":"Gargiulo L, Ibba L, Pavia G et al (Epub 2022) Real-life effectiveness and safety of risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study. Dermatol Ther (Heidelb) 12(10):2309\u20132324. https:\/\/doi.org\/10.1007\/s13555-022-00795-x","DOI":"10.1007\/s13555-022-00795-x"},{"issue":"5","key":"3500_CR3","doi-asserted-by":"publisher","first-page":"e15378","DOI":"10.1111\/dth.15378","volume":"35","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Susca S, Megna M et al (2022) Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatol Ther 35(5):e15378. https:\/\/doi.org\/10.1111\/dth.15378Epub 2022 Feb 28","journal-title":"Dermatol Ther"},{"key":"3500_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2024.02.030","author":"A Martorell","year":"2024","unstructured":"Martorell A, Santos-Alarc\u00f3n S, Sahuquillo-Torralba A et al (2024) Real-world safety and efficacy of risankizumab in psoriatic patients: a multicenter, retrospective, and not-interventional study. Actas Dermosifiliogr :S. https:\/\/doi.org\/10.1016\/j.ad.2024.02.030. 0001-7310(24)00187-X","journal-title":"Actas Dermosifiliogr :S"},{"issue":"11","key":"3500_CR5","doi-asserted-by":"publisher","first-page":"adv00605","DOI":"10.2340\/actadv.v101.283","volume":"101","author":"RG Borroni","year":"2021","unstructured":"Borroni RG, Malagoli P, Gargiulo L et al (2021) Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study. Acta Derm Venereol 101(11):adv00605. https:\/\/doi.org\/10.2340\/actadv.v101.283","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"3500_CR6","doi-asserted-by":"publisher","first-page":"e15524","DOI":"10.1111\/dth.15524","volume":"35","author":"M Megna","year":"2022","unstructured":"Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G (2022) Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther 35(7):e15524. https:\/\/doi.org\/10.1111\/dth.15524","journal-title":"Dermatol Ther"},{"issue":"9","key":"3500_CR7","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/jcm12093233","volume":"12","author":"M Megna","year":"2023","unstructured":"Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L (2023) Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study. J Clin Med 12(9):3233. https:\/\/doi.org\/10.3390\/jcm12093233","journal-title":"J Clin Med"},{"issue":"1","key":"3500_CR8","doi-asserted-by":"publisher","first-page":"2358150","DOI":"10.1080\/09546634.2024.2358150","volume":"35","author":"D Orsini","year":"2024","unstructured":"Orsini D, Assorgi C, Bonifati C, Cameli N, Graceffa D, Potestio L, Megna M (2024) Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study). J Dermatolog Treat 35(1):2358150. https:\/\/doi.org\/10.1080\/09546634.2024.2358150","journal-title":"J Dermatolog Treat"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03500-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03500-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03500-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T16:08:06Z","timestamp":1732205286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03500-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":8,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3500"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03500-4","relation":{},"ISSN":["1432-069X"],"issn-type":[{"type":"electronic","value":"1432-069X"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Source(s) of support"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"741"}}